GlassScriptPhysician profile
John Guirguis
NPI 1972922466
$820.62
in general payments reported to CMS, 2019-2025
16 companies · $241 in 2025
The $241 reported for 2025 was less than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
See the full distribution for Nephrology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $18.60 · 2021: $32.06 · 2022: $150 · 2023: $195 · 2024: $185 · 2025: $241.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $524 · Education: $96.54.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $523.85 |
| Education | $96.54 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $172.70 | 2025 | |
| Aurinia Pharma U.S., INC. | $138.42 | 2022-2024 | Lupkynis |
| Amgen INC. | $91.40 | 2022-2025 | Tavneos, Krystexxa |
| Opko Pharmaceuticals, LLC | $89.53 | 2022-2023 | Rayaldee |
| Bayer Healthcare Pharmaceuticals INC. | $62.02 | 2022-2023 | |
| Travere Therapeutics, INC. | $45.47 | 2024 | |
| Calliditas Therapeutics US INC. | $38.12 | 2022-2023 | Tarpeyo |
| Otsuka America Pharmaceutical, INC. | $31.09 | 2021-2023 | Jynarque |
| Akebia Therapeutics INC | $24.61 | 2024 | Vafseo |
| Boehringer Ingelheim Pharmaceuticals, INC. | $23.65 | 2024 | Jardiance |
| Genzyme Corporation | $23.48 | 2023 | |
| Mallinckrodt Hospital Products INC. | $18.60 | 2020 | |
| Lilly USA, LLC | $17.29 | 2023 | Jardiance |
| Astrazeneca Pharmaceuticals LP | $16.27 | 2021 | |
| Vifor Pharma, INC. | $15.27 | 2024 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ardelyx, INC. | $12.70 | 2023 | Ibsrela |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Guirguis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.